published meta-analysis   sensitivity analysis   studies

potential COVID-19 treatments in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsSekine (PLACOVID), 2021 2.14 [0.70; 6.58] 2.14[0.70; 6.58]Sekine (PLACOVID), 202110%160NAnot evaluable death D28detailed resultsAbuhasira, 2021 0.72 [0.23; 2.24] AlQahtani, 2020 0.47 [0.04; 5.69] Aman, 2021 0.51 [0.27; 0.96] Amra, 2021 0.47 [0.12; 1.93] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.02 [0.62; 1.68] Davoudi-Monfared, 2020 0.30 [0.11; 0.83] Fragoso-Saavedra (PISCO), 2020 0.32 [0.13; 0.80] Gharebaghi, 2020 0.00 [0.00; 0.09] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Jamaati, 2021 1.19 [0.38; 3.72] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Li, 2020 0.59 [0.22; 1.59] NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55] O’Donnell, 2021 0.47 [0.21; 1.06] PICP19 (Ray), 2020 0.67 [0.30; 1.51] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Raman, 2021 0.49 [0.02; 15.10] RECOVER, 2021 1.09 [0.38; 3.13] REMAP-CAP, fixed 7-day course, 2020 1.03 [0.54; 1.98] REMAP-CAP, shock-dependent course, 2020 1.10 [0.58; 2.10] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Tabarsi, 2020 1.10 [0.45; 2.67] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] Zhang, 2020 0.50 [0.17; 1.50] 0.80[0.67; 0.95]Abuhasira, 2021, AlQahtani, 2020, Aman, 2021, Amra, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Davoudi-Monfared, 2020, Fragoso-Saavedra (PISCO), 2020, Gharebaghi, 2020, HYDRA (Hernandez-Cardenas), 2021, Jamaati, 2021, Kalil (ACTT-3), 2021, Li, 2020, NCT04377750 (HMO-0224-20), 0, O’Donnell, 2021, PICP19 (Ray), 2020, PlasmAr, 2020, Pouladzadeh, 2021, Raman, 2021, RECOVER, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021, Zhang, 20203428%5,917moderatecritical death or transfer to ICUdetailed resultsLopardo, 2021 0.65 [0.35; 1.22] 0.65[0.35; 1.22]Lopardo, 202110%241NAnot evaluable deathsdetailed resultsAlQahtani, 2020 0.47 [0.04; 5.69] Aman, 2021 0.51 [0.27; 0.96] Cao, 2020 0.71 [0.36; 1.40] CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] CAPE-COVID, 2020 0.45 [0.20; 1.02] CAPSID, 2021 0.84 [0.28; 2.50] COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] CODEX (Tomazini), 2020 0.97 [0.72; 1.31] COLCHIVID, 2021 0.69 [0.20; 2.40] CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] COV-BARRIER (critically ill), 2022 0.54 [0.31; 0.95] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] COVID-VIT-D, 2022 1.48 [0.75; 2.92] CP-COVID-19, 2021 3.20 [0.62; 16.39] Darazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] Davoudi-Monfared, 2020 0.38 [0.16; 0.87] DEVENT, 0 0.47 [0.22; 1.00] DEXA-COVID19, 2020 2.00 [0.21; 18.87] Duke University hydroxychloroquine/azithromycine, 2020 0.50 [0.01; 19.56] Edalatifard, 2020 0.29 [0.15; 0.56] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] Gharebaghi, 2020 0.00 [0.00; 0.09] Hamed, 2021 1.83 [0.16; 21.66] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] ILBS-COVID-02 (Bajpai M), 2020 3.82 [0.35; 41.96] INSPIRATION, 2021 1.09 [0.78; 1.53] Jamaati, 2021 1.19 [0.38; 3.72] Jamali Moghadam Siahkali, 2021 1.00 [0.19; 5.40] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Kumar, 2021 0.06 [0.00; 1.35] Kumari, 2020 0.60 [0.22; 1.64] Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12] Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50] Li, 2020 0.59 [0.22; 1.59] Lopardo, 2021 0.57 [0.24; 1.37] Ming Zhong, 2020 0.17 [0.02; 1.44] NCT04377750 (HMO-0224-20), 0 0.48 [0.15; 1.55] Okumuş, 2020 0.58 [0.18; 1.91] O’Donnell, 2021 0.47 [0.21; 1.06] PICP19 (Ray), 2020 0.67 [0.30; 1.51] PlasmAr, 2020 0.93 [0.47; 1.85] Pouladzadeh, 2021 0.31 [0.01; 10.20] Rahmani, 2020 0.29 [0.05; 1.56] Raman, 2021 0.49 [0.02; 15.10] Rasheed, 2020 0.13 [0.01; 1.09] RECOVER, 2021 1.09 [0.38; 3.13] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] REMAP-CAP (plasma), 2021 0.96 [0.80; 1.15] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] REMAP-CAP sarilumab, 2021 0.51 [0.25; 1.07] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.08 [0.85; 1.38] REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45] REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] sarilumab phase 2 high dose, 0 0.78 [0.34; 1.80] sarimulab phase 2 low dose, 0 1.51 [0.69; 3.32] Sekine (PLACOVID), 2021 1.38 [0.73; 2.62] Shi, 2020 0.53 [0.01; 27.55] Shu, 2020 0.38 [0.02; 8.14] Singh (TD-0903 1mg), 2021 0.40 [0.03; 6.18] Singh (TD-0903 3mg), 2021 0.15 [0.01; 4.34] Steroids-SARI, 2020 0.91 [0.29; 2.86] Tabarsi, 2020 1.10 [0.45; 2.67] Talaschian, 2021 1.25 [0.30; 5.14] Veiga, 2021 2.70 [0.92; 7.92] Zhang, 2020 0.50 [0.17; 1.50] 0.81[0.72; 0.90]AlQahtani, 2020, Aman, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, CAPE-COVID, 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COLCHIVID, 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, COVID-VIT-D, 2022, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, DEVENT, 0, DEXA-COVID19, 2020, Duke University hydroxychloroquine/azithromycine, 2020, Edalatifard, 2020, Fragoso-Saavedra (PISCO), 2020, Gharebaghi, 2020, Hamed, 2021, HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, INSPIRATION, 2021, Jamaati, 2021, Jamali Moghadam Siahkali, 2021, Kalil (ACTT-3), 2021, Kumar, 2021, Kumari, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, Lopardo, 2021, Ming Zhong, 2020, NCT04377750 (HMO-0224-20), 0, Okumuş, 2020, O’Donnell, 2021, PICP19 (Ray), 2020, PlasmAr, 2020, Pouladzadeh, 2021, Rahmani, 2020, Raman, 2021, Rasheed, 2020, RECOVER, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Steroids-SARI, 2020, Tabarsi, 2020, Talaschian, 2021, Veiga, 2021, Zhang, 20206932%15,353moderatecritical deaths (time to event analysis only)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47] COVACTA (Rosas), 2020 1.16 [0.73; 1.84] CP-COVID-19, 2021 3.20 [0.62; 16.39] Davoudi-Monfared, 2020 0.38 [0.16; 0.87] Edalatifard, 2020 0.29 [0.15; 0.56] Fragoso-Saavedra (PISCO), 2020 0.33 [0.14; 0.79] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] PlasmAr, 2020 0.93 [0.47; 1.85] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93] REMAP-CAP, fixed 7-day course, 2020 0.94 [0.61; 1.45] REMAP-CAP, shock-dependent course, 2020 0.98 [0.63; 1.53] Rosas (REMDACTA), 2021 0.95 [0.65; 1.39] Talaschian, 2021 1.25 [0.30; 5.14] Zhang, 2020 0.50 [0.17; 1.50] 0.80[0.66; 0.98]COALITION II Covid-19 Brazil (Furtado), 2020, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Davoudi-Monfared, 2020, Edalatifard, 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, PlasmAr, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Talaschian, 2021, Zhang, 20201652%5,093moderatelow clinical deteriorationdetailed resultsCAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] CAPSID, 2021 0.63 [0.29; 1.40] CODEX (Tomazini), 2020 0.66 [0.43; 1.02] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] Shu, 2020 0.27 [0.01; 5.58] Zhang, 2020 0.40 [0.10; 1.65] 0.69[0.52; 0.91]CAP-China (Wang et al.), 2020, CAPSID, 2021, CODEX (Tomazini), 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Shu, 2020, Zhang, 202060%868moderatenot evaluable clinical improvementdetailed resultsCao, 2020 1.31 [0.94; 1.83] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] CAPSID, 2021 1.58 [0.71; 3.49] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] COV-BARRIER (critically ill), 2022 2.87 [1.12; 7.36] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Davoudi-Monfared, 2020 1.10 [0.64; 1.88] Edalatifard, 2020 12.00 [2.39; 60.20] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Li, 2020 1.40 [0.79; 2.49] Lopardo, 2021 1.61 [0.75; 3.49] Okumuş, 2020 1.51 [0.54; 4.24] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 0.81 [0.50; 1.31] Pouladzadeh, 2021 7.31 [1.62; 32.97] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] REMAP-CAP sarilumab, 2021 1.76 [1.12; 2.78] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 0.83 [0.67; 1.03] REMAP-CAP, fixed 7-day course, 2020 1.43 [0.91; 2.26] REMAP-CAP, shock-dependent course, 2020 1.22 [0.76; 1.95] sarilumab phase 2 high dose, 0 2.09 [1.00; 4.36] sarimulab phase 2 low dose, 0 1.51 [0.73; 3.11] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shu, 2020 10.27 [1.17; 90.18] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.24[1.08; 1.42]Cao, 2020, CAP-China (Wang et al.), 2020, CAPSID, 2021, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Edalatifard, 2020, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Li, 2020, Lopardo, 2021, Okumuş, 2020, O’Donnell, 2021, PlasmAr, 2020, Pouladzadeh, 2021, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (tocilizumab), 2021, REMAP-CAP sarilumab, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 20212960%7,416moderatecritical clinical improvement (14-day)detailed resultsCao, 2020 1.94 [1.09; 3.48] CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07] COV-BARRIER (critically ill), 2022 1.97 [0.95; 4.09] Kalil (ACTT-3), 2021 1.01 [0.79; 1.29] Li, 2020 2.27 [0.90; 5.72] REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06] REMAP-CAP sarilumab, 2021 1.86 [1.20; 2.87] REMAP-CAP, fixed 7-day course, 2020 1.29 [0.82; 2.03] REMAP-CAP, shock-dependent course, 2020 1.03 [0.65; 1.64] Shu, 2020 10.27 [1.17; 90.18] 1.18[0.93; 1.49]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, Kalil (ACTT-3), 2021, Li, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP sarilumab, 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Shu, 20201265%4,045moderatecritical clinical improvement (28-day)detailed resultsAbuhasira, 2021 1.70 [0.52; 5.49] Cao, 2020 1.59 [0.84; 3.03] CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04] COV-BARRIER (critically ill), 2022 1.82 [0.87; 3.81] COVACTA (Rosas), 2020 1.19 [0.81; 1.75] Li, 2020 1.42 [0.65; 3.10] O’Donnell, 2021 1.38 [0.73; 2.61] Pouladzadeh, 2021 7.31 [1.62; 32.97] Sekine (PLACOVID), 2021 0.94 [0.74; 1.19] Shu, 2020 3.68 [0.18; 75.54] Singh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 3.00 [0.20; 45.25] 1.24[0.98; 1.57]Abuhasira, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, COV-BARRIER (critically ill), 2022, COVACTA (Rosas), 2020, Li, 2020, O’Donnell, 2021, Pouladzadeh, 2021, Sekine (PLACOVID), 2021, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 20211338%2,047moderatecritical clinical improvement (7-day)detailed resultsCao, 2020 3.16 [0.62; 16.06] CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40] Li, 2020 0.98 [0.27; 3.58] Shu, 2020 6.72 [1.50; 30.07] 1.54[0.73; 3.24]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, Li, 2020, Shu, 2020549%976moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsAbuhasira, 2021 1.22 [0.70; 2.14] Cao, 2020 1.31 [0.94; 1.83] CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] Darazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Davoudi-Monfared, 2020 1.10 [0.64; 1.88] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41] Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54] Li, 2020 1.40 [0.79; 2.49] O’Donnell, 2021 1.20 [0.87; 1.65] PlasmAr, 2020 1.00 [0.76; 1.32] Rahmani, 2020 3.41 [1.33; 8.73] 1.13[1.02; 1.25]Abuhasira, 2021, Cao, 2020, CAP-China (Wang et al.), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, HYDRA (Hernandez-Cardenas), 2021, Kalil (ACTT-3), 2021, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Li, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 20201416%2,877moderatecritical death or ventilationdetailed resultsCAPE-COVID, 2020 0.71 [0.37; 1.35] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] Fragoso-Saavedra (PISCO), 2020 0.46 [0.22; 0.96] REMAP-CAP, fixed 7-day course, 2020 2.74 [1.16; 6.46] REMAP-CAP, shock-dependent course, 2020 1.24 [0.55; 2.78] Rosas (REMDACTA), 2021 0.98 [0.72; 1.34] sarilumab phase 2 high dose, 0 0.39 [0.18; 0.82] sarimulab phase 2 low dose, 0 0.70 [0.34; 1.44] Veiga, 2021 1.54 [0.65; 3.63] 0.84[0.60; 1.20]CAPE-COVID, 2020, CORIMUNO-TOCI-1 (Group 1), 2020, Fragoso-Saavedra (PISCO), 2020, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Veiga, 2021958%1,732moderatenot evaluable hospital dischargedetailed resultsCAPE-COVID, 2020 1.67 [0.87; 3.19] COLCHIVID, 2021 1.13 [0.76; 1.67] Davoudi-Monfared, 2020 1.96 [0.76; 5.03] Fragoso-Saavedra (PISCO), 2020 1.13 [0.82; 1.55] HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] Rahmani, 2020 3.44 [0.64; 18.49] REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92] Rosas (REMDACTA), 2021 0.97 [0.79; 1.20] 1.00[0.84; 1.19]CAPE-COVID, 2020, COLCHIVID, 2021, Davoudi-Monfared, 2020, Fragoso-Saavedra (PISCO), 2020, HYDRA (Hernandez-Cardenas), 2021, Rahmani, 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, Rosas (REMDACTA), 2021950%2,524moderateserious mechanical ventilationdetailed resultsAbuhasira, 2021 1.62 [0.41; 6.39] AlQahtani, 2020 0.67 [0.22; 2.02] CAPE-COVID, 2020 0.95 [0.44; 2.04] COVACTA (Rosas), 2020 0.67 [0.39; 1.14] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Davoudi-Monfared, 2020 0.72 [0.29; 1.76] Fragoso-Saavedra (PISCO), 2020 0.85 [0.27; 2.62] Hamed, 2021 3.15 [0.57; 17.48] Jamaati, 2021 1.38 [0.45; 4.20] Jamali Moghadam Siahkali, 2021 1.30 [0.31; 5.40] Kumari, 2020 0.76 [0.33; 1.76] O’Donnell, 2021 1.50 [0.47; 4.82] PlasmAr, 2020 0.86 [0.39; 1.93] Rahmani, 2020 0.29 [0.05; 1.56] sarilumab phase 2 high dose, 0 0.27 [0.10; 0.71] sarimulab phase 2 low dose, 0 0.28 [0.11; 0.73] Shu, 2020 0.59 [0.02; 14.04] Singh (TD-0903 1mg), 2021 0.09 [0.00; 2.48] Singh (TD-0903 3mg), 2021 0.08 [0.00; 2.07] Tabarsi, 2020 1.49 [0.59; 3.78] 0.78[0.60; 1.01]Abuhasira, 2021, AlQahtani, 2020, CAPE-COVID, 2020, COVACTA (Rosas), 2020, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Fragoso-Saavedra (PISCO), 2020, Hamed, 2021, Jamaati, 2021, Jamali Moghadam Siahkali, 2021, Kumari, 2020, O’Donnell, 2021, PlasmAr, 2020, Rahmani, 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Tabarsi, 20202113%2,226moderatelow mechanical ventilation (time to event analysis only)detailed resultsCP-COVID-19, 2021 0.66 [0.25; 1.72] Fragoso-Saavedra (PISCO), 2020 0.81 [0.27; 2.42] 0.72[0.35; 1.48]CP-COVID-19, 2021, Fragoso-Saavedra (PISCO), 202020%288moderatenot evaluable radiologic improvement (14-day)detailed resultsJamaati, 2021 4.89 [1.15; 20.79] Tabarsi, 2020 2.33 [0.45; 12.00] 3.53[1.19; 10.46]Jamaati, 2021, Tabarsi, 202020%134moderatenot evaluable viral clearance detailed resultsCP-COVID-19, 2021 1.12 [0.16; 7.84] Raman, 2021 36.42 [10.85; 122.18] 6.97[0.23; 210.35]CP-COVID-19, 2021, Raman, 2021289%200moderatenot evaluable viral clearance by day 14detailed resultsCP-COVID-19, 2021 1.51 [0.33; 6.94] Raman, 2021 36.42 [10.85; 122.18] 7.68[0.34; 173.70]CP-COVID-19, 2021, Raman, 2021290%200moderatenot evaluable ICU admissiondetailed resultsAbuhasira, 2021 1.96 [0.51; 7.52] COVACTA (Rosas), 2020 0.48 [0.25; 0.94] CP-COVID-19, 2021 0.82 [0.35; 1.91] Darazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Hamed, 2021 3.15 [0.57; 17.48] Lopardo, 2021 0.67 [0.35; 1.28] Rahmani, 2020 0.37 [0.14; 1.00] Tabarsi, 2020 0.56 [0.18; 1.74] 0.67[0.47; 0.95]Abuhasira, 2021, COVACTA (Rosas), 2020, CP-COVID-19, 2021, Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Hamed, 2021, Lopardo, 2021, Rahmani, 2020, Tabarsi, 202098%875moderatenot evaluable Major thrombotic events or deathdetailed resultsREMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.04 [0.80; 1.36] 1.04[0.80; 1.36]REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202110%1,091NAnot evaluable off oxygenationdetailed resultsDavoudi-Monfared, 2020 8.57 [1.43; 51.36] HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] ILBS-COVID-02 (Bajpai M), 2020 0.26 [0.02; 2.88] sarilumab phase 2 high dose, 0 1.99 [0.95; 4.15] sarimulab phase 2 low dose, 0 1.07 [0.52; 2.21] 1.35[0.75; 2.46]Davoudi-Monfared, 2020, HYDRA (Hernandez-Cardenas), 2021, ILBS-COVID-02 (Bajpai M), 2020, sarilumab phase 2 high dose, 0, sarimulab phase 2 low dose, 0555%545seriousnot evaluable recoverydetailed resultsCOV-BARRIER (critically ill), 2022 1.57 [0.77; 3.20] Talaschian, 2021 0.64 [0.14; 2.92] 1.30[0.64; 2.66]COV-BARRIER (critically ill), 2022, Talaschian, 202129%137lownot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable related AE (TRAE)detailed resultsSingh (TD-0903 1mg), 2021 2.50 [0.16; 38.60] Singh (TD-0903 3mg), 2021 0.38 [0.01; 13.93] 1.26[0.14; 11.07]Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 202120%25moderatenot evaluable related SAE (TRSAE)detailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11] 1.24[0.50; 3.11]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable serious adverse eventsdetailed resultsCao, 2020 0.52 [0.27; 1.01] CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77] CODEX (Tomazini), 2020 0.53 [0.17; 1.62] COVACTA (Rosas), 2020 0.81 [0.54; 1.22] Edalatifard, 2020 0.81 [0.11; 6.17] Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12] Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51] O’Donnell, 2021 0.64 [0.35; 1.17] PlasmAr, 2020 1.40 [0.78; 2.51] Raman, 2021 0.49 [0.02; 15.10] REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49] REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33] REMAP-CAP (plasma), 2021 2.28 [1.17; 4.46] REMAP-CAP, fixed 7-day course, 2020 3.01 [0.33; 27.32] REMAP-CAP, shock-dependent course, 2020 3.68 [0.42; 31.96] Rosas (REMDACTA), 2021 0.83 [0.59; 1.18] Sekine (PLACOVID), 2021 1.14 [0.88; 1.48] Shi, 2020 1.08 [0.04; 32.96] Talaschian, 2021 7.93 [0.37; 171.38] Veiga, 2021 1.66 [0.60; 4.59] 1.04[0.87; 1.24]Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, CODEX (Tomazini), 2020, COVACTA (Rosas), 2020, Edalatifard, 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, O’Donnell, 2021, PlasmAr, 2020, Raman, 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020, REMAP-CAP (plasma), 2021, REMAP-CAP, fixed 7-day course, 2020, REMAP-CAP, shock-dependent course, 2020, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Talaschian, 2021, Veiga, 20212127%7,352moderatelow superinfectiondetailed resultsCAPE-COVID, 2020 0.81 [0.49; 1.34] Davoudi-Monfared, 2020 2.41 [0.75; 7.73] Rahmani, 2020 0.18 [0.02; 1.59] 0.91[0.32; 2.60]CAPE-COVID, 2020, Davoudi-Monfared, 2020, Rahmani, 2020360%296moderatenot evaluable adverse eventsdetailed resultsCOVACTA (Rosas), 2020 0.87 [0.52; 1.45] Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69] Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27] Raman, 2021 1.36 [0.56; 3.30] Rosas (REMDACTA), 2021 1.32 [0.92; 1.89] Sekine (PLACOVID), 2021 1.08 [0.85; 1.38] Shi, 2020 0.88 [0.38; 2.03] Shu, 2020 2.48 [0.05; 132.54] Singh (TD-0903 1mg), 2021 0.45 [0.01; 16.71] Singh (TD-0903 3mg), 2021 0.04 [0.00; 1.01] Veiga, 2021 1.65 [0.81; 3.37] 1.12[0.96; 1.31]COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Raman, 2021, Rosas (REMDACTA), 2021, Sekine (PLACOVID), 2021, Shi, 2020, Shu, 2020, Singh (TD-0903 1mg), 2021, Singh (TD-0903 3mg), 2021, Veiga, 2021110%2,137moderatelow deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] 0.36[0.13; 1.01]CAP-China (Wang et al.), 202010%233NAnot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] 1.09[0.42; 2.79]CAP-China (Wang et al.), 202010%233NAnot evaluable long QTdetailed resultsCOALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43] 0.90[0.56; 1.43]COALITION II Covid-19 Brazil (Furtado), 202010%439NAnot evaluable Major bleedingdetailed resultsINSPIRATION, 2021 1.83 [0.53; 6.34] REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 2021 1.48 [0.74; 2.98] 1.56[0.85; 2.87]INSPIRATION, 2021, REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients), 202120%1,653moderatenot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11] 1.44[0.98; 2.10]CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 202020%672moderatenot evaluable Thromboembolic eventsdetailed resultsINSPIRATION, 2021 1.07 [0.76; 1.49] 1.07[0.76; 1.49]INSPIRATION, 202110%562NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-05-08 19:24 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439 - roots T: 290